Performance of Previously Identified Predictors of >=15% Body Weight Reduction with Tirzepatide in Participants with Type 2 Diabetes in SURMOUNT-2

被引：0
|
作者：
Lingvay, Ildiko
Malecki, Maciej
Benabbad, Imane
Falcon, Beverly
Lee, Clare
Wang, Hui
Dunn, Julia P.
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-815-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
815-P
引用
收藏
页数：3
相关论文
共 50 条
  • [1] SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide
    Frandsen, Christian Seerup
    Madsbad, Sten
    LANCET, 2023, 402 (10402): : 586 - 588
  • [2] Effect of tirzepatide on kidney parameters in people with excess body weight and type 2 diabetes: a post-hoc analysis of the SURMOUNT-2 trial
    Heerspink, H. J. L.
    Friedman, A. N.
    Bjornstad, P.
    van Raalte, D. H.
    Cao, D.
    Garcia-Perez, L. -E.
    Stefanski, A.
    Turfanda, I.
    Bunck, M. C.
    Benabbad, I.
    de Oliveira, C. Piras
    Griffin, R.
    DIABETOLOGIA, 2024, 67 : S355 - S356
  • [3] Effect of Tirzepatide on Kidney Function in People with Excess Body Weight and Type 2 Diabetes-A Post-Hoc Analysis of the SURMOUNT-2 Trial
    Heerspink, Hiddo L.
    Friedman, Allon
    Bjornstad, Petter
    Van Raalte, Daniel
    Cao, Dachuang
    Garcia-Perez, Luis-Emilio
    Stefanski, Adam
    Turfanda, Ibrahim
    Bunck, Mathijs C.
    Benabbad, Imane
    De Oliveira, Carolina Piras
    Griffin, Ryan
    DIABETES, 2024, 73
  • [4] Weight Reduction Is Associated with Improved Quality of Life in Participants with Obesity or Overweight and Type 2 Diabetes-Results from Phase 3 SURMOUNT-2 Trial
    Gibble, Theresa Hunter
    Cao, Dachuang
    Zhang, Michelle X.
    Xavier, Neena Agarwal
    Poon, Jiat Ling
    DIABETES, 2024, 73
  • [5] Differences in Weight Reduction Efficacy of Tirzepatide in Adults Without vs. With Type 2 Diabetes with Overweight or Obesity in SURMOUNT 1 and 2
    Galindo, Rodolfo J.
    Garvey, W. Timothy
    Neff, Lisa M.
    Stefanski, Adam
    Cao, Dachuang
    Lee, Clare
    DIABETES, 2024, 73
  • [6] The Effect of Tirzepatide vs. Placebo on Changes and Shifts in BMI Category in Adults with Type 2 Diabetes-A Post Hoc Analysis of the SURMOUNT-2 Study
    Galindo, Rodolfo J.
    Lazarus, Ethan
    Wang, Hui
    Garcia-Perez, Luis-Emilio
    Zhang, Michelle X.
    Grant, Gary
    Malik, Raleigh
    DIABETES, 2024, 73
  • [7] Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4
    Malecki, Maciej T.
    Batterham, Rachel L.
    Sattar, Naveed
    Levine, Joshua A.
    Rodriguez, Angel
    Bergman, Brandon K.
    Wang, Hui
    Ghimpeteanu, Gabriela
    Lee, Clare J.
    DIABETES CARE, 2023, 46 (12) : 2292 - 2299
  • [8] Early Weight Loss and Cardiometabolic Parameters in Tirzepatide-Treated Participants in SURMOUNT 1-2
    Thethi, Tina
    Kokkinos, Alexander
    McKean-Matthews, Missy
    Lee, Clare
    Neff, Lisa
    Mast, Casey
    Rodriguez, Angel
    Stefanski, Adam
    Bartee, Amy
    OBESITY, 2024, 32 : 34 - 34
  • [9] Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial
    Theresa Hunter Gibble
    Dachuang Cao
    Xiaotian Michelle Zhang
    Neena Agarwal Xavier
    Jiat Ling Poon
    Angela Fitch
    Diabetes Therapy, 2025, 16 (5) : 977 - 991
  • [10] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
    Garvey, W. Timothy
    Frias, Juan P.
    Jastreboff, Ania M.
    Roux, Carel W. le
    Sattar, Naveed
    Aizenberg, Diego
    Mao, Huzhang
    Zhang, Shuyu
    Ahmad, Nadia N.
    Bunck, Mathijs C.
    Benabbad, Imane
    Zhang, Xiaotian M.
    LANCET, 2023, 402 (10402): : 613 - 626
12345